{"denoms":[{"counts":[{"groupId":"BG000","value":"300"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"450"}],"units":"Participants"}],"groups":[{"description":"Taken orally twice daily","id":"BG000","title":"Olaparib 300mg Tablets (Global Cohort & China Cohort)"},{"description":"Taken orally twice daily","id":"BG001","title":"Placebo Tablets (Global Cohort & China Cohort)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.38","value":"53.6"},{"groupId":"BG001","spread":"9.79","value":"53.4"},{"groupId":"BG002","spread":"9.51","value":"53.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"391"}],"units":"Participants"}],"title":"Global Cohort"},{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.27","value":"50.7"},{"groupId":"BG001","spread":"7.95","value":"51.5"},{"groupId":"BG002","spread":"7.44","value":"51.0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"64"}],"units":"Participants"}],"title":"China Cohort"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"391"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"391"}],"units":"Participants"}],"title":"Global Cohort"},{"categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"64"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"64"}],"units":"Participants"}],"title":"China Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"59"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"214"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"320"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"391"}],"units":"Participants"}],"title":"Global Cohort"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"64"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"64"}],"units":"Participants"}],"title":"China Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"213"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"320"}],"title":"Complete Response"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"71"}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"391"}],"units":"Participants"}],"title":"Global Cohort"},{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"55"}],"title":"Complete Response"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"64"}],"units":"Participants"}],"title":"China Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.","title":"Response to previous platinum chemotherapy (as randomised)","unitOfMeasure":"Participants"}],"populationDescription":"Global Cohort (391 subjects):\n\n260 Olaparib 131 Placebo\n\nChina Cohort (64 subjects):\n\n44 Olaparib 20 Placebo\n\nIncluded in both cohorts (5 subjects):\n\n4 Olaparib\n\n1 Placebo\n\nTotal (450 subjects):\n\n300 Olaparib 150 Placebo"}